The global FiteBac Project continues to include more scientists from universities and industries throughout the world who are creating advanced composites, coatings, textiles, and drug applications. For 11 years, founder Dr. Kirk Kimmerling and a team of over 30 scientists and dental researchers have brought FiteBac Technology to the forefront of Antimicrobial Dentistry. Dedicated and passionate researchers have created built-in authority with dozens of scientific publications providing the evidence and proof that lead to FiteBac’s composition of matter antimicrobial patents, as well as FDA recognition of FiteBac’s lead molecules K18 and K21 in cleared antimicrobial dental devices.